Condition: Cutaneous T-Cell Lymphoma/Mycosis Fungoides · Sponsor: miRagen Therapeutics, Inc.
The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype in subjects who have confirmed disease progression following treatment with vorinostat in the SOLAR clinical study (MRG106-11-201). Cobomarsen is designed to inhibit the activity of a molecule called miR-155 that may be important to the growth and survival of MF cancer cells. The effects of treatment will be measured based on changes in skin lesion severity, disease-associated symptoms, and quality of life, as well as the length of time that the subject's disease remains stable or improved, without evidence of disease progression. The safety and tolerability of cobomarsen will be assessed based on the frequency and severity of observed side effects.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Mayo Clinic Hospital | Phoenix, Arizona, United States | — |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | — |
| Washington University School of Medicine | St Louis, Missouri, United States | — |
| The Ohio State University and Wexner Medical Center | Columbus, Ohio, United States | — |
| University of Washington/Seattle Cancer Care Alliance | Seattle, Washington, United States | — |
| University Hospital Leuven | Leuven, Belgium | — |
| Hopital Saint Andre, CHU de Bordeaux | Bordeaux, France | — |
| Hopital Saint-Louis | Paris, France | — |
| Hopital Charles Nicolle, CHU de Rouen | Rouen, France | — |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03837457